Zacks Investment Research cut shares of ELEKTA AB/ADR (OTCMKTS:EKTAY) from a hold rating to a sell rating in a research note published on Tuesday, Zacks.com reports.
According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “
Separately, ValuEngine downgraded shares of ELEKTA AB/ADR from a buy rating to a hold rating in a report on Tuesday, April 9th.
Shares of ELEKTA AB/ADR stock opened at $11.59 on Tuesday. The firm has a market cap of $4.31 billion, a price-to-earnings ratio of 32.50, a PEG ratio of 2.79 and a beta of 0.52. The company has a quick ratio of 0.93, a current ratio of 1.18 and a debt-to-equity ratio of 0.62. ELEKTA AB/ADR has a one year low of $10.75 and a one year high of $14.61.
ELEKTA AB/ADR (OTCMKTS:EKTAY) last announced its quarterly earnings data on Friday, February 22nd. The company reported $0.06 EPS for the quarter. The company had revenue of $367.04 million during the quarter. ELEKTA AB/ADR had a net margin of 9.35% and a return on equity of 16.86%. On average, equities research analysts forecast that ELEKTA AB/ADR will post 0.35 earnings per share for the current year.
The firm also recently disclosed a Semi-Annual dividend, which was paid on Friday, March 22nd. Investors of record on Monday, March 4th were paid a $0.052 dividend. The ex-dividend date was Friday, March 1st. ELEKTA AB/ADR’s payout ratio is 28.57%.
About ELEKTA AB/ADR
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.
See Also: What is Cost of Goods Sold (COGS)?
Get a free copy of the Zacks research report on ELEKTA AB/ADR (EKTAY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.